GAINESVILLE, Fla. — December 23, 2011 — Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences
company that is developing innovative technologies for the healthcare and consumer markets,
announced today that the U.S. Patent Office has issued a Notice of Allowance for the method of
production that non-leachably bonds NIMBUS antimicrobials to various treated substrates.
The patent that is to be issued covers the process of attaching members of the NIMBUS family
of antimicrobials to substrates that are whole or in part cellulosic or any of a list of other
substrates including such polymerics as polyurethane, polyester, nylon and acrylics, as well as
silk, linen, rubber, alginates and collagen among many others. These are materials that are
commonly used in textile and medical products, filters, absorbent products and packaging.
Non-leachable bonding of the antimicrobial agent distinguishes NIMBUS from other
antimicrobial materials which require release of the active agent in order to function. In such
products the antimicrobial is depleted gradually. These antimicrobials carry the risk of irritation
or interference with healing in products such as wound dressings and textile applications in which
the treated material is next to or used on the skin.
This newest of the Quick-Med Technologies series of patents is a keystone of the NIMBUS
technology in that it covers the process of treating materials such that they become permanent
barriers to the transmission of microorganisms. The resulting materials do not allow depletion of
the active agent which can lead to damage to human skin or tissue cells such that they can cause
irritation, delay healing and possibly initiate the development of bacterial resistance.
The Company expects the patent to issue in mid-January.
Posted on January 3, 2012
Source: Quick-Med Technologies
